Literature DB >> 21726191

High content pharmacophores from molecular fields: a biologically relevant method for comparing and understanding ligands.

Timothy J Cheeseright1, Mark D Mackey, Robert A Scoffin.   

Abstract

The question of how and why a small molecule binds to a protein is central to ligand-based drug discovery. The traditional way of approaching these questions is pharmacophore analysis. However, pharmacophores as usually applied lack quantitation and subtlety. An improvement is to consider the electrostatic and steric fields of the ligand directly. Molecular fields provide a rich view of the potential interactions that a molecule can make and can be validated through experimental data on molecular interactions and through quantum mechanics calculations. A technique is presented in this review for comparing molecules using molecular fields and assigning similarity scores. This high information content method can be used to align molecules for SAR analysis, to determine the bioactive conformation from ligand data, and to screen large libraries of compounds for structurally unrelated actives. An extension to allow interactive exploration of chemistry space via bioisostere analysis is also reviewed. Examples from the literature showing the success of these methods are presented, and future directions discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21726191     DOI: 10.2174/157340911796504314

Source DB:  PubMed          Journal:  Curr Comput Aided Drug Des        ISSN: 1573-4099            Impact factor:   1.606


  15 in total

1.  Exploring Modifications of an HIV-1 Capsid Inhibitor: Design, Synthesis, and Mechanism of Action.

Authors:  Jimmy P Xu; Ashwanth C Francis; Megan E Meuser; Marie Mankowski; Roger G Ptak; Adel A Rashad; Gregory B Melikyan; Simon Cocklin
Journal:  J Drug Des Res       Date:  2018-08-13

2.  Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Ni Cheng; Richard D Ye; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2014-10-17       Impact factor: 5.858

Review 3.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

4.  Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement.

Authors:  Marina Tuyishime; Matt Danish; Amy Princiotto; Marie K Mankowski; Rae Lawrence; Henry-Georges Lombart; Kirill Esikov; Joel Berniac; Kuang Liang; Jingjing Ji; Roger G Ptak; Navid Madani; Simon Cocklin
Journal:  Bioorg Med Chem Lett       Date:  2014-12-01       Impact factor: 2.823

5.  Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.

Authors:  Enza Lacivita; Igor A Schepetkin; Madia L Stama; Liliya N Kirpotina; Nicola A Colabufo; Roberto Perrone; Andrei I Khlebnikov; Mark T Quinn; Marcello Leopoldo
Journal:  Bioorg Med Chem       Date:  2014-12-13       Impact factor: 3.641

Review 6.  Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn
Journal:  Int Immunopharmacol       Date:  2015-09-15       Impact factor: 4.932

7.  Identification of a small molecule HIV-1 inhibitor that targets the capsid hexamer.

Authors:  Jimmy P Xu; Jeffrey D Branson; Rae Lawrence; Simon Cocklin
Journal:  Bioorg Med Chem Lett       Date:  2015-12-25       Impact factor: 2.823

8.  3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Marcello Leopoldo; Ermelinda Lucente; Enza Lacivita; Paola De Giorgio; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2012-12-03       Impact factor: 5.858

9.  Core chemotype diversification in the HIV-1 entry inhibitor class using field-based bioisosteric replacement.

Authors:  Marina Tuyishime; Rae Lawrence; Simon Cocklin
Journal:  Bioorg Med Chem Lett       Date:  2015-10-27       Impact factor: 2.823

10.  Rapid Optimization of the Metabolic Stability of a Human Immunodeficiency Virus Type-1 Capsid Inhibitor Using a Multistep Computational Workflow.

Authors:  Megan E Meuser; Poli Adi Narayana Reddy; Alexej Dick; Jean Marc Maurancy; Joseph M Salvino; Simon Cocklin
Journal:  J Med Chem       Date:  2021-03-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.